Introduction
Randomized controlled trials are one of the strongest forms of clinical evidence, with results that critically impact patient care. However, the majority of randomized trials are considered 'negative', i.e. fail to demonstrate a statistical difference between the arms of the study for the primary end point [1] [2] [3] . On one hand, a preponderance of negative randomized studies is consistent with the principle of equipoise; on the other hand, it signals a lack of clinical successes [4] . In retrospect, a negative clinical trial often cannot be distinguished from one that is simply underpowered, and, there is substantial evidence that many clinical trials are underpowered [5] [6] [7] [8] [9] .
Many have expressed concern regarding the negative impact of underpowered clinical trials on both the scientific community and patient care [10] [11] [12] [13] [14] . First, such trials are unlikely to detect a benefit of the experimental intervention, which squanders resources and hinders the advancement of scientific knowledge [10, 11] . Second, underpowered trials increase the risk that a (potentially effective) intervention is perceived as ineffective, when such evidence is weak or dubious. As others have noted, 'the absence of evidence is not the evidence of absence' [12] . Third, some underpowered trials may be considered ethically problematic, since patients are exposed to the potential harms of interventions with a low likelihood of determining whether there is a benefit [13, 14] . Of note, however, underpowered trials are not universally considered unacceptable, since some information is generally considered better than no information, and ultimately small studies have the potential to be combined with others in a systematic review [15] .
Nonetheless, 'optimism bias', or the unwarranted belief in the efficacy of new treatments, has been identified as a culprit leading to underpowered clinical trials [16] . A previous review of all phase III Radiation Therapy Oncology Group (RTOG) clinical trials conducted from 1968 to 2002 found that many trials were designed to detect unrealistically large effect sizes, and in most trials there was no substantial difference between outcomes in the experimental and standard treatment arms [17] . Overestimating effect sizes were also shown to contribute to inconclusive findings in phase III National Cancer Institute (NCI) cooperative group clinical trials conducted and published from 1955 to 2006 [18] .
We therefore sought to evaluate the role of 'optimism bias' in contemporary National Clinical Trial Network (NCTN) phase III trials. Our primary aims were to determine if contemporary NCTN phase III trials were more successful at detecting the benefit of new therapies compared with older trials published between 1955 and 2006 [18] , whether these trials were powered to achieve realistic effect sizes, and whether the trial protocols provided a rationale supporting their proposed effect sizes.
Methods

Data source
We conducted a systematic review of NCTN phase III randomized controlled trials. These trials are funded by the NCI and conducted with high methodological quality, including a rigorous peer-review and approval process by the cooperative group committees [19] . A previous review of older NCI sponsored clinical trials published between 1955 and 2006 also provided a useful benchmark to measure potential improvements in design and outcomes of contemporary NCTN trials [18] .
We queried PubMed for all phase III randomized trials published between January 2007 and January 2017 from seven NCI-sponsored cooperative groups: National Surgical Adjuvant Breast and Bowel Project, RTOG, North Central Cancer Treatment Group, Southwest Oncology Group, Gynecology Oncology Group, Eastern Cooperative Oncology Group, and Cancer and Leukemia Group B. We chose to only include studies published in peer-reviewed journals, to ensure the most complete data analysis and follow-up. We limited the analysis to phase III studies since these trials ideally have the best preclinical and early clinical data to inform estimation of treatment effects. We included trials that were published but closed early due to futility, toxicity, or slow accrual. Equivalence or noninferiority trials, trials with missing protocols, trials that accrued less than 40% of their intended sample size, and trials that pooled their data with other studies were excluded (Figure 1) .
Clinical trial protocols were retrieved from the Clinical Trials Support Unit website or by contacting cooperative group staff. We compared the proposed effect size from the a priori sample size calculation in the clinical trial protocol to the observed effect size in the published report. If the effect on the primary end point was statistically significant (P < 0.05) and favored the experimental treatment, a trial was classified as 'positive'; otherwise, the trial was classified as 'negative'. For studies that were published multiple times at intervals of longer follow-up, we used the most recent publication with the longest follow-up data. For trials that randomized patients to more than two treatment arms, we recorded the data from the best and worst arms. For trials with coprimary end points, only the overall survival end point was used in our analysis.
We first reviewed the statistical methods sections of protocols to determine if there was any evidence, reference, or rationale provided to support the proposed effect size. If there was no explanation or citation in the statistical methods section, we then reviewed the introduction and background sections to determine if a rationale was provided for the proposed effect size. For trials that modified the sample size calculation during the course of the study, the most updated effect size was included in the analysis.
Statistical analysis
For trials reporting time-to-event outcomes with hazard ratios (HRs), we compared the hypothesized effect size from the research protocol with the observed effect size in the published article to calculate the ratio of observed-to-expected HRs. All HRs were standardized for a reduction in adverse outcomes relative to the standard control group, such that HRs <1 indicated a benefit to experimental therapy. In this case, a ratio of observed-to-expected HRs >1 indicates effect size overestimation. For trials that did not report the observed HR, we extracted data from the published Kaplan-Meier curves using Engauge Digitizer version 10.8 [20] and computed HRs using the spreadsheet developed by Tierney et al. [21] .
Logistic regression and Pearson correlation were used to test for factors predictive of clinical trial success (i.e. statistically significant effect on the primary end point favoring experimental therapy). Chi-square tests were used to test for differences between trial success and presence of 
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rationale for the protocol effect size. All analyses were carried out using R version 3.2.2 [22] .
Results
We identified 161 clinical trials of which 130 were eligible for analysis. Research protocols could not be located for eight trials (5.0%; Figure 1 ). The majority of trials were in the primary setting and the most common primary end point was overall survival ( Table 1 ). The most common malignancy was breast cancer, followed by gynecologic, gastrointestinal, and genitourinary cancers. Most trials had a single primary end point with equal allocation between two arms and a parallel design (i.e. no crossover between arms). Twenty-eight trials (21.5%) observed a statistically significant difference in the primary end point favoring the experimental treatment, compared with 24.6% for NCI trials conducted and published from 1955 to 2006 [1, 18] . There was no correlation between treatment success and sample size, primary end point, year of publication, or intent of therapy, which indicates the unpredictability of treatment success in randomized trials.
The median hypothesized HR for all trials was 0.71 (range: 0.46-0.83), and the median observed HR was 0.91 (range: 0.18-1.31) (Figure 2 ). The most common hypothesized effect sizes were a 25% or 33% reduction in the primary outcome (HR ¼ 0.75 or 0.67), which were collectively used in 27 protocols (32.9%) and are represented by the 'horns' in Figure 2 . Unsurprisingly, the median observed effect size was larger for positive trials (0.72; range: 0.18-0.85) than negative trials (0.96; range: 0.68-1.31). Observed treatment effects favored the experimental therapy (i.e. HR < 1) in 70.7% of trials.
Most trials hypothesized effect sizes that were larger than observed (Figure 3 ). Only eight trials (9.8%) observed an effect size at least as large as the one projected in the protocol, compared with 17% of NCI trials published from 1955 to 2006 [18] . The median ratio of observed-to-expected HRs was 1.28 (range: 0.33-2.02). The median ratio of observed-to-expected HRs among positive trials was 1.07 (range: 0.33-1.28) versus 1.32 (range: 0.86-2.02) for negative trials. In comparison, for NCI trials published from 1955 to 2006, these ratios were 1.34 and 1.86, respectively [18] .
Among all trials, 84 (64.6%) provided no rationale to justify the magnitude of the hypothesized effect size in the protocol. Trials with a toxicity primary end point (n ¼ 32) were more likely to provide a rationale than other trials (71.9% versus 23.4%; P < 0.001); however, these were often based on the assumption that a meaningful clinical effect is equivalent to one half standard deviation change in the primary end point, rather than prior evidence [23, 24] . Among trials that provided a rationale for the proposed effect size, 26.1% observed a statistically significant result favoring the experimental arm compared with 19.0% of trials that did not (P ¼ 0.48).
Discussion
In this study, we sought to determine what role 'optimism bias' might play in contemporary phase III trials in oncology. We found that most contemporary NCTN phase III trials were negative, and only 9.8% of positive trials reported an effect size at least as large as the one proposed in the protocol. We also found no identifiable predictors of treatment success, indicating the continued unpredictability of randomized trial results. This is fortunate since unpredictability is critical for both patients and medical providers to ensure treatment arms are balanced and trial participation is ethical.
Although it is unclear what the ideal ratio of observed-toexpected HRs should be, examining trends can inform us as to whether we are persistently overestimating effect sizes. We found that this ratio appears to have decreased in modern NCTN clinical trials. Improvements in clinical trial design and methodology as well as improved preclinical and early clinical screening (i.e. bringing more promising therapies into phase III trials) may be responsible for this favorable finding. However, this did not increase the proportion of positive trials, which may illustrate the challenge of maintaining sustained progress in disease settings that have already experienced a substantial increase in survival over the past half century. Of note, there are also important methodological differences between the evaluation of NCI sponsored trials in the two eras; the current study only evaluated observedto-expected HRs for time-to-event data, whereas the prior analysis included both HRs and odds ratios.
Comparison of trials between different eras can also be impacted by improvements in clinical trial methodology, cancer imaging and staging, and cancer therapy. These changes can affect the efficiency of trials, the classification of patients (i.e. stage migration), and the available treatment options. Sustained advances in cancer therapy and supportive care can pose a barrier for further improvements to survival. Importantly, however, the general framework for hypothesis testing has remained stable, allowing for an objective comparison of treatment success between eras.
Because hypothesized effect sizes critically affect the estimated sample size, cost, and feasibility of clinical trials, its basis (such as data from prior phase II or phase III trials) ideally should be explained in the protocol. Unfortunately, investigators are frequently incentivized to tinker with the hypothesized effect in order to engineer a desired sample size, in a process referred to as the 'sample size samba' [25] . While some degree of 'samba' may be necessary given budgetary constraints and the complexities of modern clinical trial design, effect sizes should also be realistic and supported by prior evidence [16, 26] . In addition to being clinically meaningful, an effect size must also be plausible [10, 11] . Consider a proposed randomized trial of a green peashooter versus a red peashooter for the treatment of cancer. While it is mathematically possible to 'power' such a trial for any given effect size, its true power is nil, since there is no mechanistic basis for a difference in outcomes (of any size). Still, in most clinical trial protocols we reviewed, we could find no rationale to justify the magnitude of the hypothesized effect size.
Strengths of this study include analysis and comparison of a large and comprehensive cohort of published randomized controlled trials with their associated research protocols. To our knowledge, our study is also the first to report on the proportion of phase III clinical trial protocols in oncology that provided rationale for the magnitude of the proposed primary effect size. An unexpected obstacle we encountered was the difficulty in obtaining research protocols, even though these were large publically funded phase III trials. Some journals have recently begun requiring clinical trial protocols to be published alongside manuscripts in order to strengthen peer review and improve readers' ability to interpret the study results. However, the practice of publishing protocols has not become widespread and better measures are needed to ensure transparency of clinical trial research.
However, this study has several limitations. Our analysis omitted trials that were closed early and were never published. Including these trials would increase the proportion of trials that did not demonstrate effectiveness of new interventions. Another caveat is that our study is a post hoc analysis, and as such we cannot distinguish a negative trial from an underpowered trial. The categorization of trials as either positive or negative is also somewhat simplistic, since these studies provide important information on secondary end points and allow subgroup analyses. For instance, a negative clinical trial can still provide valuable information regarding toxicity, convenience, and quality of life end points. However, the primary end point ultimately determines the size, cost, and feasibility of a given trial. While investigators may be basing their effect sizes on prior data yet failing to cite sources in their protocols, clearly a need for better transparency exists. Unfortunately, reporting of sample size calculation parameters has been inadequate in contemporary clinical trials [27, 28] .
Conclusion
In conclusion, our study reinforces the notion that investigators tend to overestimate the effectiveness of new interventions; however, the magnitude of this problem appears to have decreased in contemporary NCTN trials. While CONSORT guidelines already mandate the reporting of sample size calculations in randomized controlled trial protocols [29] , a clear rationale supporting the hypothesized effect size should be included as well, ideally based on evidence from prior research. Better measures to ensure accessibility of research protocols is also needed to improve transparency and reproducibility of publishing findings.
